伊立替康联合氟尿嘧啶治疗晚期胃腺癌临床观察(1)
参见附件(12kb)。
【摘要】 目的 评价伊立替康联合氟尿嘧啶双周方案治疗晚期胃腺癌的疗效和不良反应。方法 38例初治的晚期胃腺癌患者，伊立替康150 mg/m2 静脉滴注第1天，亚叶酸钙200 mg/m2 静脉滴注第一天，随后氟尿嘧啶2200 mg/m2 持续微量泵静脉推注46 h，14 d为一周期。根据实体瘤疗效评价标准对客观缓解率进行评价，不良反应按美国国立癌症研究所制定的通用药物毒性评价标准(第3版)进行评价。结果 35例患者可评价疗效，无完全缓解患者，部分缓解(PR)10例，稳定(SD)8例，进展(PD)17例，总有效率28.6%，疾病控制率51.4%，中位肿瘤进展时间3.2个月，中位生存期8.5个月，1年生存率31.4%。最常见的不良反应为骨髓抑制、呕吐和迟发性腹泻，多为I、Ⅱ级，患者耐受良好。结论 伊立替康联合氟尿嘧啶双周方案治疗晚期胃腺癌，具有较好的疗效和安全性，值得临床上进一步试用。
【关键词】 伊立替康；氟尿嘧啶；亚叶酸钙；胃癌
Clinical observation of Irinotecan and 5-Fluorouracil in advanced gastric adenocarcinom ZHUANG Ling-hua, YAN Wen-hua, YANG Xiang-hua.Department of Medical Oncology, Fujian Provincial Jianou Civil Hospital, Jianou 353100, China
【Abstract】 Objective To observe the efficacy and toxicity of Irinotecan and 5-Fluorouracil in advanced gastric adenocarcinom. Methods A total of 38 advanced gastric adenocarcinom patients received Irinotecan 150 mg/m2 and Calcium Folinate 200 mg/m2 d1, followed by 5-Fluorouracil 2200 mg/m2 for 46 hour by the intravenous administration with 14 days as a cycle in the first line. The objective response rate was estimated by RECIST and the toxicity was estimated by CTC-AE 3.0. Results 35 patients were evaluabled. No one CR，10 patients PR, 8 patients SD, 17 patients PD. The objective response rate(ORR) was 28.6%. The disease control rate(DCR) was 51.4%. The median progression-free survival (PFS) was 3.2 months. The median overall survival (OS) was 8.5 months. The one year survival rate was 31.4%. The most commonly seen adverse events (AEs) were myelosuppression, vomit and diarrhea with grade I and grade Ⅱ toxicity. The adverse events were tolerated. Conclusion The Irinotecan and 5-Fluorouracil is effective and safe in treating patients with in advanced gastric adenocarcinom.
【Key words】 Irinotecan; 5-Fluorouracil; Calcium Folinate; Gastric cancer
作者单位：353100 福建省建瓯市立医院肿瘤内科
胃癌是消化道最常见的恶性肿瘤之一 ......
【摘要】 目的 评价伊立替康联合氟尿嘧啶双周方案治疗晚期胃腺癌的疗效和不良反应。方法 38例初治的晚期胃腺癌患者，伊立替康150 mg/m2 静脉滴注第1天，亚叶酸钙200 mg/m2 静脉滴注第一天，随后氟尿嘧啶2200 mg/m2 持续微量泵静脉推注46 h，14 d为一周期。根据实体瘤疗效评价标准对客观缓解率进行评价，不良反应按美国国立癌症研究所制定的通用药物毒性评价标准(第3版)进行评价。结果 35例患者可评价疗效，无完全缓解患者，部分缓解(PR)10例，稳定(SD)8例，进展(PD)17例，总有效率28.6%，疾病控制率51.4%，中位肿瘤进展时间3.2个月，中位生存期8.5个月，1年生存率31.4%。最常见的不良反应为骨髓抑制、呕吐和迟发性腹泻，多为I、Ⅱ级，患者耐受良好。结论 伊立替康联合氟尿嘧啶双周方案治疗晚期胃腺癌，具有较好的疗效和安全性，值得临床上进一步试用。
【关键词】 伊立替康；氟尿嘧啶；亚叶酸钙；胃癌
Clinical observation of Irinotecan and 5-Fluorouracil in advanced gastric adenocarcinom ZHUANG Ling-hua, YAN Wen-hua, YANG Xiang-hua.Department of Medical Oncology, Fujian Provincial Jianou Civil Hospital, Jianou 353100, China
【Abstract】 Objective To observe the efficacy and toxicity of Irinotecan and 5-Fluorouracil in advanced gastric adenocarcinom. Methods A total of 38 advanced gastric adenocarcinom patients received Irinotecan 150 mg/m2 and Calcium Folinate 200 mg/m2 d1, followed by 5-Fluorouracil 2200 mg/m2 for 46 hour by the intravenous administration with 14 days as a cycle in the first line. The objective response rate was estimated by RECIST and the toxicity was estimated by CTC-AE 3.0. Results 35 patients were evaluabled. No one CR，10 patients PR, 8 patients SD, 17 patients PD. The objective response rate(ORR) was 28.6%. The disease control rate(DCR) was 51.4%. The median progression-free survival (PFS) was 3.2 months. The median overall survival (OS) was 8.5 months. The one year survival rate was 31.4%. The most commonly seen adverse events (AEs) were myelosuppression, vomit and diarrhea with grade I and grade Ⅱ toxicity. The adverse events were tolerated. Conclusion The Irinotecan and 5-Fluorouracil is effective and safe in treating patients with in advanced gastric adenocarcinom.
【Key words】 Irinotecan; 5-Fluorouracil; Calcium Folinate; Gastric cancer
作者单位：353100 福建省建瓯市立医院肿瘤内科
胃癌是消化道最常见的恶性肿瘤之一 ......
您现在查看是摘要介绍页，详见PDF附件(12kb)。